Why Jasper Therapeutics Stock Is Falling Today – Benzinga

Posted: October 16, 2021 at 2:56 am

Jasper Therapeutics Inc (NASDAQ: JSPR) is trading lower Thursday amidprofit taking after the stock rallied roughly 120% on Wednesday.

Jasper Therapeuticssurgedhigher Wednesday afterOppenheimer analyst Jay Olson initiatedcoverage on the stockwith anOutperform rating and announced aprice target of$21.

The Oppenheimer analyst cited the potential of Jasper Therapeutics' conditioning agents for hematopoietic stem cell transplantation.

Jasper Therapeutics went public via special purpose acquisition companyAmplitude Healthcare Acquisition Corporation at the end of September.

Jasper Therapeuticsis a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It'sfocused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

JSPR Price Action:Jasper Therapeutics was down 16% at $12.42 at time of publication.

View More Analyst Ratings for JSPR View the Latest Analyst Ratings

2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

View post:
Why Jasper Therapeutics Stock Is Falling Today - Benzinga

Related Post